BioCryst Pharmaceuticals (BCRX) Projected to Post Quarterly Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Monday, May 5th. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.07) per share and revenue of $126.83 million for the quarter.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. The business's revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.28 earnings per share. On average, analysts expect BioCryst Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioCryst Pharmaceuticals Stock Up 2.1 %

Shares of BCRX stock opened at $8.39 on Monday. BioCryst Pharmaceuticals has a 52 week low of $4.11 and a 52 week high of $9.50. The firm has a 50 day moving average of $7.72 and a 200-day moving average of $7.76. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -13.75 and a beta of 1.75.

Analysts Set New Price Targets

Several equities research analysts have weighed in on BCRX shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $11.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, April 11th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Evercore ISI raised their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Needham & Company LLC restated a "buy" rating and set a $15.00 price objective on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. Finally, Wedbush began coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 target price on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.